News About: Pharm. Industry
Teva-Handok acquires domestic approval of asthma/COPD therapyA Handok-Teva’s(CEO Sun-dong Park) asthma and chronic obstructive pulmonary disease(COPD) treatment, Duorespi Spiromax(generic name: budesonide/formoterol) acquired approval fro...
|
Will MSD get out of NIP if their prices are unified?It’s a very tough situation. The government has shut their mount, and the two pharmaceutical companies concerned have shown no sign to shorten their gap in opinion.
This is the...
|
Domestic pharmaceutical companies win Trajenta’s crystalline patent nullification trial
Domestic pharmaceutical companies have won the crystalline patent nullification trial of ‘Trajenta,’ a new DPP-4 type antidiabetic.
Including Trajenta Duo, Trajenta imported by Boehringer and sold by Yuhan Corporatio...
Listed pharmaceuticals’ sales promotion activities weakened by MERS and ethical management
As the listed pharmaceutical companies’ sales promotion activities have been weakened due to the spread of MERS and ethical management, their expenses related were also analyzed to be reduced.
According to the Yakup ...
Multinational pharmaceutical tightening promotion standards
Foreign pharmaceutical companies have strengthened their promotion activity standards higher than what it is in the industry. They are basically showing their will to get away from any suspicion while domestic pharmac...
Alexion Korea selects Wolman disease treatment as first drug to introduceAlexion, a U.S. rare disease pharmaceutical company getting ready for its Korean branch, has decided the first pharmaceutical product to introduce in the domestic market.
It is...
|
Pharmaceutical association’s extreme action to reveal rebate-suspicious companies
The Korea Pharmaceutical Manufacturers Association has decided to reveal the ‘Secrete Rebate Survey’ result at a board meeting on the 22nd.
The reveal will be made internally, not outside. Although a part of the indu...
8 of 10 ECCO members trust Celltrion’s RemsimaAt the 11th European Crohn’s and Colitis Organization(ECCO) held in Amsterdam, Netherlands from 16th to 19th of March, a survey was announced 8 of 10 ECCO members trust biosimil...
|
Average pharmaceutical companies’ inventory asset turnover period is 65 days
It was analyzed it takes about 65 days for a listed pharmaceutical company’s manufactured product in a storage to be exhausted.
According to the Yakup Shinmoon’s(www.yakup.com) analysis result of KOSPI and KOSDAQ lis...
‘Biosimilar’ development takes largest portion in pharmaceutical R&D expensess
A field with the largest pharmaceutical R&D expenses was turned out to be the biosimilar field.
The Korea Health Industry Development Institute announced through the recent ‘2014 Pharmaceutical Product/Medical Devic...
